The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global eubiotics market is expected to exhibit a CAGR of 7.41% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Eubiotics refer to various feed additives used to improve the digestive health in poultry, swine, livestock and aquatic animals. They are natural digestive stimulants and are used as a substitute to antibiotics in the feed. Eubiotics commonly include probiotics, prebiotics, essential oils and organic acids that enhance nutrient absorption, enhance immunity and increase overall performance. They aid in maintaining a healthy balance of microbiota, such as bacteria, archaea, protists and fungi, in the gastrointestinal tract and are essential for immunologic, hormonal and metabolic homeostasis.
The increasing prevalence of livestock diseases across the globe represents one of the key factors creating a positive outlook for the market. Consumption of eubiotics-based feed provides essential nutrients and health and medicinal benefits to livestock, such as prevention and timely treatment of chronic diseases. Furthermore, increasing awareness among consumers regarding feed quality and safety also driving the market growth. Eubiotics are widely used as an alternative for antibiotic growth promoters (AGPs) in animals and livestock. In line with this, the growing demand for animal meat and protein is also contributing to the increasing demand for Eubiotics. Additionally, various technological advancements, such as the use of innovative microbiological solutions to develop novel product variants with targeted results and easy digestibility, are contributing to the market growth. Other factors, including the rapid modernization of the livestock industry, along with increasing domestication of animals as pets, especially in the developed countries, are anticipated to drive the market further.
IMARC Group provides an analysis of the key trends in each sub-segment of the global eubiotics market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, form, application and end use.
Breakup by Product:
Breakup by Form:
Breakup by Application:
Breakup by End Use:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Advanced Bionutrition Corp., Behn Meyer Holding AG, Beneo Gmbh (Südzucker AG), Calpis Co. Ltd. (Asahi Group Holdings Ltd.), Koninklijke DSM N.V., DuPont de Nemours Inc., Kemin Industries Inc., Lallemand Inc., Lesaffre, Novus International Inc. (Mitsui & Co. Ltd.) and UAS Laboratories LLC (Chr. Hansen Holding A/S).
|Base Year of the Analysis||2021|
|Segment Coverage||Product, Form, Application, End Use, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Advanced Bionutrition Corp., Behn Meyer Holding AG, Beneo Gmbh (Südzucker AG), Calpis Co. Ltd. (Asahi Group Holdings Ltd.), Koninklijke DSM N.V., DuPont de Nemours Inc., Kemin Industries Inc., Lallemand Inc., Lesaffre, Novus International Inc. (Mitsui & Co. Ltd.) and UAS Laboratories LLC (Chr. Hansen Holding A/S)|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Immunotherapy Drugs Market by Type (Monoclonal Antibodies, Vaccines, Interferons Alpha and Beta, Interleukins), Therapy Area (Cancer, Autoimmune and Inflammatory Diseases, Infectious Diseases, and Others), End User (Hospitals, Clinics, and Others), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at